Csaba P. Kovesdy declares consultancy work for Abbott, Akebia, AstraZeneca, Bayer, Boehringer Ingelheim, Cara Therapeutics, CSL Vifor, GlaxoSmithKline, ProKidney, Pharmacosmos, and Takeda. Natalie Ebert declares receiving honoraria from Bayer AG. Mikhail N. Kosiborod has received institutional research grants from AstraZeneca, Boehringer Ingelheim, and Pfizer; performed consultancy/advisory board work from 35Pharma, Alnylam, Amgen, Applied Therapeutics, Arrowhead Pharmaceuticals, AstraZeneca, Bayer, Boehringer Ingelheim, Corcept Therapeutics, Cytokinetics, Dexcom, Eli Lilly, Esperion Therapeutics, Imbria Pharmaceuticals, Janssen, Lexicon Pharmaceuticals, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pfizer, Pharmacosmos, Regeneron, Sanofi, scPharmaceuticals, Structure Therapeutics, Vifor Pharma, and Youngene Therapeutics; received other research support (data analytic center fees – payments to institution) from AstraZeneca and Vifor Pharma; received institutional honoraria from AstraZeneca, Boehringer Ingelheim, and Novo Nordisk; and holds personal stock options with Artera Health and Saghmos Therapeutics. J. Bradley Layton, Ryan Ziemiecki, Catherine B. Johannes, and Manel Pladevall-Vila are employees of RTI Health Solutions, which received research funding from Bayer AG. Bishnu Bahadur Thapa, Mudit Bhartia, and Luis Rangel are employees of OM1 Inc., which received research funding from Bayer AG. Gary Curhan is an employee of OM1 Inc., which received research funding from Bayer AG, and has also been a consultant for Atom Bioscience; received grant support from GSK and is a Section Editor and Author for UpToDate. Michael Walsh, Patrick O. Gee, Nichole Jefferson, Annie Chicoye, and Maria Lopes have no conflicts of interest. Fangfang Liu, Alfredo E. Farjat, and Nikolaus G. Oberprieler are employees of Bayer. David Vizcaya was an employee of Bayer at the time the study was carried out and is currently an employee of Alexion Pharmaceuticals S.L., Barcelona, Spain.
PubMed
